ProPhase Labs Overview
DCF fair value estimate for ProPhase Labs: $-0.31.
Get informed when a big investor buys or sells
+ Follow$-0.31
Overvalued by 1643.5% based on the discounted cash flow analysis.
ProPhase Labs (PRPH) currently reports a DCF fair value of $-0.31. Use the charts on this page to explore ProPhase Labs's DCF fair value history and peer comparisons.
ProPhase Labs's discounted cash flow (DCF) fair value estimate is $-0.31, about 1643.5% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $-0.31, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ProPhase Labs, and consider following PRPH for alerts when major investors trade the stock.
ProPhase Labs is classified in the Healthcare sector. On DCF fair value, it currently shows $-0.31. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRPH with unrelated industries.
